Podcasts about feshbach

Our guest this week is Dan Feshbach of Sausalito, CA, a serial entrepreneur and CEO of Multiple, a non-profit (501c3) innovation platform for the autism community, whose mission is 'to transform the lives of people with autism at scale.'Dan and his x-wife, were married for 35 years and are the proud parents of 30 year old twins: Emma and Reed, who is Autistic. We'll learn about Dan's many innovations and the leadership roles he played at: LoanPerformance, the Oak Hill School of California, BlueUmbrella, TeachTown, MeasureOne, Multiple and the Autism Impact Fund. That's all on this episode of SFN Dad to Dad Podcast.Show Links:Email – dan@multiplehub.orgWebsite – https://www.multiplehub.org/Website - https://niadart.org/Website - https://autismimpact.fund/Special Fathers Network - SFN is a dad to dad mentoring program for fathers raising children with special needs. Many of the 500+ SFN Mentor Fathers, who are raising kids with special needs, have said: "I wish there was something like this when we first received our child's diagnosis. I felt so isolated. There was no one within my family, at work, at church or within my friend group who understood or could relate to what I was going through."SFN Mentor Fathers share their experiences with younger dads closer to the beginning of their journey raising a child with the same or similar special needs. The SFN Mentor Fathers do NOT offer legal or medical advice, that is what lawyers and doctors do. They simply share their experiences and how they have made the most of challenging situations.Check out the 21CD YouTube Channel with dozens of videos on topics relevant to dads raising children with special needs - https://www.youtube.com/channe... Please support the SFN. Click here to donate: https://21stcenturydads.org/do...Special Fathers Network: https://21stcenturydads.org/SFN Dads Mastermind Group - https://21stcenturydads.org/sfn-mastermind-group/Discover more about the Dads Honor Ride 2023 - https://21stcenturydads.org/2023-dads-honor-ride/Find out about Horizon Therapeutics – Science and Compassion Working Together To Transform Lives. https://www.horizontherapeutics.com/

Today's show rundown: The Big News from Mark is Earth Day was this past Friday. Chuck tells us a little about what this stuff means to him and what he thinks about Global Warming. They try to confuse pollution with climate change, Chuck thinks is a lie. Well for earth day, Mark is going to drive his 36-thousand-pound motor home and trailer to a race track and burn 150 gallons of gas while ripping through a couple sets of tires. Mark introduces us to Matt Feshbach who is going to talk to us today about stem cells. Stem Cells can be miraculous, they can be the biggest waste of money, but they have really opened the floodgates. Chuck thinks most people think like he does, babies, infants, abortions…are we right to think this way? Matt tells us it is completely different now, but embryonic stem cells are still indeed a thing. Matt goes into explaining to people what a stem cell is. It starts with the concept with a developmental cell. When we are born, we have these perinatal cells. Those cells are considered adult stem cells. These cells are in every tissue in our body. Fat underneath your skin is where you can harvest stem cells from. Even if we are aging, and even if we are sick, we still have these healthy stem cells. https://ambrosecelltherapy.com/ Matt@ambrosecelltherapy.com 1-800-520-1746 About Matt Since 2018, Matthew "Matt" Feshbach has served as founding CEO of Ambrose Cell Therapy, a Florida-based center focused on improving the lives of people living with complex chronic health conditions. The center accesses a patient's own adipose-derived stem and regenerative cells (ADRCs), ADRCs have shown potential for treating chronic diseases affecting various areas of the body. Matthew Feshbach's interest in ADRCs dates back to 2009, when he began researching stem cells as part of his investment activities. His research led to the 2011 founding of Okyanos Cell Therapy, a center he led until 2017. Prior to his work as a health care entrepreneur, Matt Feshbach found success as a hedge fund investor focused on a "short-only" strategy. Under his leadership, his investment company, Feshbach Brothers, grew from $20,000 to $1 billion in assets in only nine years. This led to the company being recognized by Piper Jaffray as the top-performing money manager over the period from 1985 to 1990. Outside of his professional activities, Mr. Feshbach has worked to give back by supporting causes focused on human rights, religious freedom, and substance abuse. He also supports the Church of Scientology, an organization he has been a member of for five decades. His other free-time pursuits include cooking, swimming, and yoga.

This week, The Pack takes a trip back to the early days of short selling only to find out that, sadly, not much has changed. In 1970, Kurt Feshbach (@Kurt_Feshbach on Twitter) was a high school dropout, described in one article as a “typical SoCal surfer” sporting long hair, flipflops and a tank top. Based on appearance alone, nobody could have known that his small company in California, Feshbach Bros., was actually one of the most feared Activist Short Sellers in the world.   Kurt takes us through his first trade (which netted him $5k) and through some of the biggest hits that, in 9 years, had Feshbach Bros. managing a billion dollars - for those keeping score, that's an annualized return (IRR) of 232.4% - not bad for high school dropout.  Kurt went to war with journalists and banks while balancing a complicated relationship with the SEC and other regulators. He was criticized at the time for using what many considered to be unorthodox investigation techniques but has now become standard practice for top-tier Activist Shorts. Kurt now runs https://bindlepaper.com. The Bindle Paper is an independent boutique research firm which produces deep dive, single-stock short research for a discrete and limited group of institutional clients. bin·dle pa·per: A clean piece of standard-size, folded paper used to contain trace evidence. Sit back, grab a drink, and enjoy the trip through time, knowledge, and experience that Kurt imparts during our fascinating conversation. “We're doomed to repeat the past no matter what. That's what it is to be alive. It's pretty dense kids who haven't figured that out by the time they're ten.... Most kids can't afford to go to Harvard and be misinformed.” ― Kurt Vonnegut 1:05 Kurt talks about how he got started and the help he had from his partners and his father. 2:42 Go directly to jail, do not pass go, do not collect $200. Hear the long list of companies whose executives ended up in prison after dealing with the Feshbach Bros.  6:05 Kurt working on the sell side of Wall St, and meets a man that showed him the light, which led him to his first short idea. 12:26 A business is born; Kurt brings in his brothers and gets some seed money from a partner to start Feshbach Brothers. 15:03 Green energy was booming in the 1980's - the problem was that most of them were frauds. Kurt made a killing exposing them, including one that claimed to create "clean" energy from human waste… turns out they were full of shit. 17:40 Kurt takes us through the process that they employed to obtain SEC filings via 1980's technology. 28:06 Kurt talks about ZZZBest and Barry Minkow, one of the biggest and best shorts on his impressive track record, as well as a few others that were absolutely amazing finds. 34:55 All that swag, congressional hearings, and Robert Flaherty. 41:19 Picking through the trash, putting the puzzle together, and working with reporters to get your story out before the internet was invented. 48:48 How the market is essentially the same 40 years later, well except for the valuations... 58:57 Kurt addresses the "rumors" that Wells Fargo killed his business 1:06:38 The SEC and 20,000 pages of thermal paper. 1:19:39  The next big thing for Kurt: The Bindle Paper.

In a league of his own as one of the first Stem Cell Treatment Entrepreneurs! Matt's approach and cycle of care is personalized towards each patient's goals of improvement. Matt has been fighting chronic degenerative battles right alongside those in need, prior to being able to practice in accordance with federal law here in the United States! There are enough hurdles put in place that ultimately lead to the inevitable failures as an entrepreneur. Matt overcomes those challenges.

Matthew Feshbach is the CEO of AMBROSE, pursuing his overarching purpose to help people with complex chronic diseases live better lives.  AMBROSE is providing the “right to try” cell therapy in accordance with the Right to Try Act, and, in complete alignment with their Mission: To help people with chronic degenerative diseases improve symptoms, function, and quality of life using adult stem cell therapy. Matt took an unconventional path throughout his business career. He did not attend college, but instead taught tennis at private homes in Silicon Valley. Through that experience, he developed professional and personal relationships with some of the most prominent leaders in the San Francisco investment community.  In 1982, he co-founded Feshbach Bros, with his brothers Kurt and Joe. Feshbach Bros. managed the first “short-only” hedge fund, and assets under management grew from $20,000 to $1 Billion in 9 years.  In 2009, he and his brother, Joe, began researching adult stem cells and their potential due to their interest in a publicly-traded company. They spoke to researchers from all over the world – Israel to Japan, Holland to Spain, and New York to Los Angeles. Their quest was to understand the best source of adult stem cells, as well as the science, technologies, and unmet medical needs that could potentially be addressed with cell therapy.  Listen to the full story on today's episode of American Real.-If you're a knowledge expert, entrepreneur, business executive, or simply an aspiring author, connect with Roger to help you Write Your First Book in 90 Days or Less!  He's helping people all over the world write their first book - let him help you too. Watch his 10 minute presentation and schedule a call to discuss your book idea with him today: https://iywebinars.com/ar-Get Roger's latest book, "The Power of Being Rich: 10 Essential Steps to Manifest What You Already Have" by clicking on this link: https://amzn.to/2TN0sFr-Do you need a hand sorting through some uncertainty? Are you craving some accountability in your life? If you answered yes, book a call on Roger's calendar to see if he can help: https://calendly.com/americanreal/20min-Subscribe to our YouTube Channel: http://bit.ly/2zVQDLO-AMERICAN REAL Website: https://americanreal.tviTunes: https://apple.co/2yPeU4AFacebook: https://facebook.com/americanrealtv/Instagram: https://www.instagram.com/AmericanRealTVTwitter: https://twitter.com/rogerbrooks/LinkedIn: https://www.linkedin.com/in/rogerlbrooks/YouTube: http://www.youtube.com/c/AmericanReal

Matt Feshbach of AMBROSE Cell Therapy comes back to Living Beyond 120 to talk more about stem cell therapy, bringing stories of real outcomes that patients have experienced after treatment. They offer an overview of stem cell therapy first, including how Feshbach harvests cells for treatment. Feshbach discusses the therapeutic cells located in a person’s fat and what role these play in the therapy. They also consider what kind of conditions can benefit from stem cell therapy. Some of the actual patient stories Feshbach covers are the treatment of people who suffer from arthritis, kidney failure, emphysema, Alzheimer’s, traumatic injury and more. They talk about how stem cell therapy needs to be utilized in a way that makes sense, as well as what people can do to improve their outcomes if they do take advantage of this kind of treatment.  About Matt Feshbach: Matthew (Matt) Feshbach is the Founder and CEO of AMBROSE Cell Therapy. AMBROSE was founded in 2017 with the mission: To help people with chronic degenerative diseases improve symptoms, function and quality of life with adult stem cell therapy. Matt has taken an unconventional path throughout his business career. He did not attend college but instead taught tennis at private homes in Silicon Valley. Through that experience he developed professional and personal relationships with a number of prominent investment managers, who inspired him to study securities analysis and begin investing himself. This led to the co-founding, with his brothers Kurt and Joe, of Feshbach Bros in 1982. Feshbach Bros. managed the first “short-only” hedge fund. Assets under management grew from $20,000 to $1 Billon in 9 years. Matt’s investment career, through the ups and downs of the stock market, spanned more than 30 years. In 2009 he and his brother, Joe, began researching adult stem cells and their potential, due to their interest in a publicly traded company. They spoke to researchers from all over the world - Israel to Japan, Holland to Spain, New York to Los Angeles, Chicago to Dallas and so on - to understand the best source of adult stem cells as well as the science, technologies and unmet medical needs they could potentially address. As a result of their research, they came to have a well-informed opinion that fat (adipose) tissue is the most accessible, abundant and potent source of adult stem and regenerative cells. As well, that the mixed population of adipose-derived stem and regenerative cells (ADRCs) could be used to address a broad spectrum of chronic diseases. This has now been validated in the published medical literature. 1 2 3 Along with his brother, Matt founded Okyanos (Oh-key-ah-nos) Cell Therapy in August 2011 in Freeport, Bahamas. The Greek God of Rivers, “Okyanos” symbolizes restoration of blood flow, which is an important mechanism of action of ADRCs. Shortly after helping to create Okyanos, Matt’s brother, Joe, sadly died of a cardiac arrest. Joe’s death prompted Matt to be even more dedicated his purpose to help patients with chronic disease with their own adult stem cells. In the Bahamas, he drafted the framework for what developed into the Bahamas Stem Cell Research and Therapy Act, while concurrently building and staffing Okyanos. Due to the uncompromising standards set by Matt, Okyanos came to be known as the first cell therapy center of excellence in the world. The passage of House Bill 810, Charlie’s Law, in Texas paved the way for Matt to once again set a new standard in cell therapy for complex chronic disease. To be specific, Charlie’s Law allows the use of investigational adult stem cell treatments in Texas for patients that have been diagnosed with a terminal illness or severe chronic disease. This is a Right-to-Try Law. The U.S Constitution - Tenth Amendment states - “The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States respectively, or to the people.” As such FDA has not taken action against drug companies or providers in the 28 states with medical marijuana laws and the 38 states with laws allowing patients who are terminally ill the right to try experimental drugs without FDA approval (Right to try Laws), respectively. Matthew Feshbach has combined his 3 decades of investment experience with his personal purpose to help others and, for a non-medical person, extraordinary knowledge of the science, technology and protocols of adult stem cell therapy to bring the highest standards of safety, care and potential effectiveness to patients in need. A Nguyen, A et al Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 170e179 Guo et al Stromal vascular fraction: A regenerative reality? Part 2: Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 180e188 JK Fraser PhD and S Kesten MD Autologous Adipose Derived Regenerative Cells: A platform for therapeutic applications Advanced Wound Healing Surgical Technology International XXIX You can contact Feschbach via email or by phone: matt@ambrosecelltherapy.com (727) 743-1510  

Mark is joined by Matt Feshbach on today's show. Matt is the Founder of AMBROSE Cell Therapy, which is a stem cell hospital. He has years of experience in the medical field and has a great understanding of healthcare options. They start off by discussing the "Right-to-Try" law that has was recently signed into law. They discuss the importance of giving terminally ill patients the right to try experimental drugs that have the chance to improve their health. Mark brings up the point that it is a basic human right to own our own biology and that the government has hijacked our basic right to make decisions on our own health. As they continue their discussion, Mark and Matt discuss the politics of getting an FDA approval for a new drug. Mark explains how the pharmaceutical companies and the government have stopped innovation by limiting it to those who can spend the billions of dollars on the approval process. Matt expands on this by explaining that the pharmaceutical companies and government benefit from these high costs, but the drug companies are not doing this to harm people. Matt explains that the stem cell research and therapy that he does is not embryonic stem cells; they are stem cells from the body's own fat. Matt also explains what a stem cell is and what the therapy can do for the patient. They include the regulations and government issues that they face with stem cell therapy. They wrap up on discussing the politics that are working against stem cell research and how insurance companies benefit from normal treatments because of government policies. Mark explains why the Affordable Care Act created an incentive for insurance companies to favor more expensive types of care. More about Matt Feshbach: Matthew (Matt) Feshbach is the Founder and CEO of AMBROSE Cell Therapy. AMBROSE was founded in 2017 with the mission: To help people with chronic degenerative diseases improve symptoms, function and quality of life with adult stem cell therapy. Matt has taken an unconventional path throughout his business career. He did not attend college but instead taught tennis at private homes in Silicon Valley. Through that experience he developed professional and personal relationships with a number of prominent investment managers, who inspired him to study securities analysis and begin investing himself. This led to the co-founding, with his brothers Kurt and Joe, of Feshbach Bros in 1982. Feshbach Bros. managed the first "short-only" hedge fund. Assets under management grew from $20,000 to $1 Billon in 9 years. Matt's investment career, through the ups and downs of the stock market, spanned more than 30 years. In 2009 he and his brother, Joe, began researching adult stem cells and their potential, due to their interest in a publicly traded company. They spoke to researchers from all over the world - Israel to Japan, Holland to Spain, New York to Los Angeles, Chicago to Dallas and so on - to understand the best source of adult stem cells as well as the science, technologies and unmet medical needs they could potentially address. As a result of their research, they came to have a well-informed opinion that fat (adipose) tissue is the most accessible, abundant and potent source of adult stem and regenerative cells. As well, that the mixed population of adipose-derived stem and regenerative cells (ADRCs) could be used to address a broad spectrum of chronic diseases. This has now been validated in the published medical literature. 1 2 3 Along with his brother, Matt founded Okyanos (Oh-key-ah-nos) Cell Therapy in August 2011 in Freeport, Bahamas. The Greek God of Rivers, "Okyanos" symbolizes restoration of blood flow, which is an important mechanism of action of ADRCs. Shortly after helping to create Okyanos, Matt's brother, Joe, sadly died of a cardiac arrest. Joe's death prompted Matt to be even more dedicated his purpose to help...

Matthew Feshbach, founder and CEO of Ambrose Cell Therapy, joins the conversation to share information about stem cell research and treatment using stem cells. Feschbach explains the difference between types of stem cells and which are most effective for reparative therapies. They talk about why the body degenerates with age, related to stem cells.  Feshbach describes the process and technology his clinic uses to harvest mesenchymal stem cells for use in therapy. They consider some of the regulatory issues involved in stem cell therapy. Feshbach describes some of the amazing results that have been seen in patients who have received the therapy to treat significant health issues. He explains what sort of lifestyle choices can optimize results from this kind of treatment. Also on the podcast, Mark and Dr. Gladden discuss the problem with staying in your comfort zone, both physically and mentally. In contrast, they describe the environments in which we grow and thrive. Special Guest: Matthew (Matt) Feshbach is the Founder and CEO of AMBROSE Cell Therapy. AMBROSE was founded in 2017 with the mission: To help people with chronic degenerative diseases improve symptoms, function and quality of life with adult stem cell therapy. Matt has taken an unconventional path throughout his business career. He did not attend college but instead taught tennis at private homes in Silicon Valley. Through that experience he developed professional and personal relationships with a number of prominent investment managers, who inspired him to study securities analysis and begin investing himself. This led to the co-founding, with his brothers Kurt and Joe, of Feshbach Bros in 1982. Feshbach Bros. managed the first “short-only” hedge fund. Assets under management grew from $20,000 to $1 Billon in 9 years. Matt’s investment career, through the ups and downs of the stock market, spanned more than 30 years. In 2009 he and his brother, Joe, began researching adult stem cells and their potential, due to their interest in a publicly traded company. They spoke to researchers from all over the world - Israel to Japan, Holland to Spain, New York to Los Angeles, Chicago to Dallas and so on - to understand the best source of adult stem cells as well as the science, technologies and unmet medical needs they could potentially address. As a result of their research, they came to have a well-informed opinion that fat (adipose) tissue is the most accessible, abundant and potent source of adult stem and regenerative cells. As well, that the mixed population of adipose-derived stem and regenerative cells (ADRCs) could be used to address a broad spectrum of chronic diseases. This has now been validated in the published medical literature. 1 2 3 Along with his brother, Matt founded Okyanos (Oh-key-ah-nos) Cell Therapy in August 2011 in Freeport, Bahamas. The Greek God of Rivers, “Okyanos” symbolizes restoration of blood flow, which is an important mechanism of action of ADRCs. Shortly after helping to create Okyanos, Matt’s brother, Joe, sadly died of a cardiac arrest. Joe’s death prompted Matt to be even more dedicated his purpose to help patients with chronic disease with their own adult stem cells. In the Bahamas, he drafted the framework for what developed into the Bahamas Stem Cell Research and Therapy Act, while concurrently building and staffing Okyanos. Due to the uncompromising standards set by Matt, Okyanos came to be known as the first cell therapy center of excellence in the world. The passage of House Bill 810, Charlie’s Law, in Texas paved the way for Matt to once again set a new standard in cell therapy for complex chronic disease. To be specific, Charlie’s Law allows the use of investigational adult stem cell treatments in Texas for patients that have been diagnosed with a terminal illness or severe chronic disease. This is a Right-to-Try Law. The U.S Constitution - Tenth Amendment states - “The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States respectively, or to the people.”   As such FDA has not taken action against drug companies or providers in the 28 states with medical marijuana laws and the 38 states with laws allowing patients who are terminally ill the right to try experimental drugs without FDA approval (Right to try Laws), respectively.   Matthew Feshbach has combined his 3 decades of investment experience with his personal purpose to help others and, for a non-medical person, extraordinary knowledge of the science, technology and protocols of adult stem cell therapy to bring the highest standards of safety, care and potential effectiveness to patients in need. 1 A Nguyen, A et al Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 170e179 2 Guo et al Stromal vascular fraction: A regenerative reality? Part 2: Current concepts and review of the literature Journal of Plastic, Reconstructive & Aesthetic Surgery (2016) 69, 180e188 3 JK Fraser PhD and S Kesten MD Autologous Adipose Derived Regenerative Cells: A platform for therapeutic applications Advanced Wound Healing Surgical Technology International XXIX You can contact Feschbach via email or by phone: matt@ambrosecelltherapy.com (727) 743-1510

A success story: How did one company achieve a higher level of talent engagement? Find out on High Level Wisdom Episode 21.

How Well Do You Know Your Crew? Listen to Alison Bloom-Feshbach on High Level Wisdom Episode 20.

The production of a quantum gas with strong long - range dipolar interactions is a major scientific goal in the research field of ultracold gases. In their ro - vibrational ground state Li -K dimers possess a large permanent dipole moment, which could possibly be exploited for the realization of such a quantum gas. A production of these molecules can be achieved by the association of Li and K at a Feshbach resonance, followed by a coherent state transfer. In this thesis, detailed theoretical an experimental preparations to achieve state transfer by means of Stimulated Raman Adiabatic Passage (STIRAP) are described. The theoretical preparations focus on the selection of an electronically excited molecular state that is suitable for STIRAP transfer. In this context, molecular transition dipole moments for both transitions involved in STIRAP transfer are predicted for the first time. This is achieved by the calculation of Franck -Condon factors and a determination of the state in which the 6Li - 40K Feshbach molecules are produced. The calculations show that state transfer by use of a single STIRAP sequence is experimentally very well feasible. Further, the optical wavelengths that are needed to address the selected states are calculated. The high accuracy of the data will allow to carry out the molecular spectroscopy in a fast and efficient manner. Further, only a comparatively narrow wavelength tuneability of the spectroscopy lasers is needed. The most suitable Feshbach resonance for the production of 6Li - 40K molecules at experimentally manageable magnetic field strengths is occurring at 155G. Experimentally, this resonance is investigated by means of cross - dimensional relaxation. The application of the technique at various magnetic field strengths in the vicinity of the 155G Feshbach resonance allows a determination of the resonance position and width with so far unreached precision. This reveals the production of molecules on the atomic side of the resonance, thereby establishing the first observation of a many body effect in the crossover regime of a narrow Feshbach resonance. Further, mass dependent factors, with which the equilibration of an induced anisotropic temperature of the trapped particle samples can be described, are experimentally determined for the first time. The type of resonance as well as the measured molecular lifetimes are found to be very well suited for STIRAP transfer. A Raman laser system is designed based on the transition wavelengths and durations of state transfer which are predicted. As the wavelengths of the Raman lasers differ widely but coherence of the light fields is needed, the technical realization of a laser system is challenging. As a part of the laser system, the construction and characterization of a reference optical resonator are presented. Laser frequency stabilization with a linewidth of approximately 500Hz and an Allan deviation below 10−12 for timespans up to several ten seconds are demonstrated. Further, the stabilization of a frequency comb to this reference laser is demonstrated. For the laser spectroscopy of electronically excited Li -K states an interferometric laser frequency stabilization will be used. The device is a commercial design, for which a calibration procedure that enhances the precision by several orders of magnitude is worked out within this thesis. The calibration scheme includes the precise measurement of the stabilization’s wavelength dependent frequency deviations by means of a frequency comb. By the implementation of several calibration steps a remaining frequency deviation of less than 5.7MHz (rms 1.6MHz) in the whole relevant wavelength range 750 - 795 nm is achieved. Only the exceptional precision of the fully calibrated device permits the usage for the Li -K spectroscopy, while the demonstrated wide tuning capability facilitates the completion of the latter in a fast and convenient manner.

This work describes experiments with quantum-degenerate atomic mixtures at ultracold temperatures, where quantum statistics determine macroscopic system properties. The first heteronuclear molecules at ultracold temperatures are formed in a quantum degenerate two-species Fermi-Fermi mixture on the repulsive side of a narrow s-wave Feshbach resonance. Elastic collisions in this mixture are investigated with the method of cross-dimensional relaxation. Long-lived two-body bound states on the atomic side of the resonance are detected due to a many-body effect at the crossover of the narrow Feshbach resonance. In addition, atom scattering with fermionic 40K on a light field grating in the Bragg and Kapitza-Dirac regimes is realized for the first time. The versatile experimental platform, where the investigations are done, offers the possibility to perform studies on mixtures involving the bosonic species 87Rb and the two fermionic species 6Li and 40K. Within this work, mainly interactions between the two fermionic species are considered. A quantum-degenerate mixture of 6Li and 40K can be used to create heteronuclear bosonic molecules close to an interspecies s-wave Feshbach resonance. By an adiabatic magnetic field sweep, up to 4 × 10^4 molecules are produced with conversion efficiencies close to 50%. A direct and sensitive molecule detection method is developed to probe molecule properties. The lifetime of the molecules in an atom-molecule mixture exhibits a strong magnetic field dependence. Close to resonance, lifetimes of more than 100ms are observed what offers excellent starting conditions for further investigation and manipulation of the molecular cloud. The interspecies Feshbach resonance, which serves for the production of molecules, is further characterized. The method of cross-dimensional relaxation is applied for the first time to a Fermi-Fermi mixture. For this method, a non-equilibrium state is created, which rethermalizes by pure interspecies collisions due to the fermionic nature of the two species. The lighter atomic species, 6Li, relaxes faster in the mixture than the heavier one, 40K. This is verified by an analytical model, Monte-Carlo simulations, and measurements. With this technique, elastic scattering cross sections are measured over a wide range of magnetic field strengths across the Feshbach resonance. The position (B0 = 154.71(5)G) and the magnetic field width of the Feshbach resonance (Delta = 1.02(7)G) are determined. By comparison of the several measurements, long-lived bound states exist on the atomic side of the resonance due to a many-body effect in the crossover regime of the resonance. In addition, atomic scattering with ultracold 40K on a light field crystal is studied for the first time. The light grating is generated by two counter-propagating laser beams. Suitable pulse parameters for the realization of atom scattering in the Bragg and Kapitza-Dirac regime are found. The momentum spread of the cloud determines the efficiency of the scattering process, which is increased by lowering the temperature of the system.

The controlled generation of entanglement forms the basis for currently emerging ‘quantum technologies’, such as quantum simulation, computation, and metrology. In the field of quantum metrology, multi-particle entangled states, such as spin-squeezed states, are investigated as a means to improve measurement precision beyond the ‘standard quantum limit’. This limit arises from the quantum noise inherent in measurements on a finite number of uncorrelated particles and limits today’s best atomic clocks. Atom chips combine exquisite coherent control of ultracold atoms with a compact and robust setup, suggesting their use for quantum metrology with portable atomic clocks and interferometers. A severe limitation of atom chips, however, is that techniques to control atomic interactions and to generate entanglement have not been experimentally available so far. In this thesis, I present experiments where we generate for the first time multi-particle entanglement on an atom chip. We achieve this by controlling elastic collisional interactions with a state-dependent potential. We employ this novel technique to generate spin-squeezed states of a two-component Bose-Einstein condensate and show that they are a useful resource for quantum metrology, as they could be used to improve an interferometric measurement by 2.5 dB over the standard quantum limit. The state-dependent potential is created with the help of a coplanar microwave guide, which is integrated on our atom chip. In the vicinity of this waveguide a microwave nearfield is formed. When a Bose-Einstein condensate of 87Rb is brought into this near-field, the hyperfine energy levels of the atoms are shifted differentially due to the AC Zeeman effect. The strong gradients in the field can be used to state-selectively shift the minimum of a static magnetic atom trap and thus coherently split an ensemble of atoms which have been prepared in a superposition of two internal states. During this process, nonlinear atomic interactions lead to the formation of a spinsqueezed state. I tomographically analyze the produced state, reconstruct its Wigner function, and deduce that it is at least four-particle entangled. I compare our results with a dynamical multi-mode simulation which takes not only the atomic motion and internal state dynamics but also particle losses into account and find good agreement. Moreover, I use this comparison to identify technical noise sources in our experiment, which currently limit the achieved amount of squeezing, and make suggestions on how to eliminate them in future experiments. Our method can in principle create a very large amount of squeezing and entanglement and is applicable to a wide variety of atomic systems, in particular to those for which no convenient Feshbach resonance exists. We envisage the implementation of this technique in portable atomic clocks and interferometers operating beyond the standard quantum limit. Furthermore, it is a valuable tool for experiments on many-body quantum physics and could enable quantum information processing on atom chips.

This thesis proposes two complementary scenarios to observe Bell correlations in the motion of two macroscopically separated material particles. Both are based on the gradual dissociation of ultracold Feshbach molecules and result in macroscopic delocalizations of the single-atom states. By giving a full account of these scenarios, including the coupled-channel description of the Feshbach dissociation, the optically guided dispersive propagation, interferometric processing and the final position measurements, I demonstrate for both cases their potential to violate a Bell inequality under experimentally viable conditions that correspond to delocalizations and interatomic separations on the order of centimeters.